Nicotinic receptor agonists for the treatment of inflammatory diseases

a technology of nicotinic receptor and inflammatory diseases, which is applied in the field of inflammatory diseases, can solve the problems of inducing addiction, crossing the blood-brain barrier, and not previously disclosed, and achieves the effect of minimizing any systemic effects and minimal side effects

Inactive Publication Date: 2010-09-09
UNIV LAVAL
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0021]The present invention thus proposes the use nicotinic receptor agonists, such as DMPP, to treat inflammatory lung diseases such as asthma, COPD, interstitial pulmonary fibrosis (IPF), sarcoidosis, HP, and bronchiolitis obliterans with organizing pneumonitis (BOOP). The drug could be administered orally, or preferably by targeted delivery directly to the lung by aerosolisation with different and preferred vehicles thus minimizing any systemic effects.
[0022]The anti-inflammatory and immunosuppressive properties, as well as minimal side effects, of nicotinic receptor agonists make these drugs ideally suited for medical use in the treatment of a large variety of lung diseases that are characterized by bronchial or interstitial inflammation. These diseases include diseases such as asthma, COPD, IPF, sarcoidosis, HP and BOOP.

Problems solved by technology

Despite the impressive anti-inflammatory and immunosuppressive properties of nicotine and other nicotinic receptor agonists, their usefulness in the treatment of allergic and other inflammatory lung diseases has not previously been disclosed.
The main problem is that nicotine crosses the blood-brain barrier, inducing addiction.
The harmful effects of cigarette smoking are obvious.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nicotinic receptor agonists for the treatment of inflammatory diseases
  • Nicotinic receptor agonists for the treatment of inflammatory diseases
  • Nicotinic receptor agonists for the treatment of inflammatory diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

In Vivo HP Studies

[0065]The hypothesis is that the stimulation of nicotinic receptors with nicotine down-regulates the immune response to HP antigens via inflammatory cytokine suppression and inhibition of specific antigen-mediated cellular activation.

[0066]This model was selected because, as mentioned previously, the incidence of HP is lower in smokers than in non-smokers (50), and because this model is well described. HP was induced by the administration of Saccharopolyspora rectivirgula (SR) antigen, the causative agent of farmer's lung (51), a form of HP. Mice were simultaneously treated with intra-peritoneal (IP) nicotine, with doses ranging from 0.5 to 2.0 mg / kg, twice a day. Nicotine administration significantly reduced the number of total cells found in the bronchoalveolar lavage (BAL) of these mice. The population that was the most affected by nicotine treatment were lymphocytes (FIG. 1). Pulmonary macrophages and lymphocytes were isolated, and stimulated with anti-CD3+reco...

example 2

In Vitro Studies Showing the Effect of Nicotinic Agonists on Cytokine Expression

[0067]To further clarify the mechanisms involved in suppressive effect of nicotine in the in vivo model, an alveolar macrophage cell line was used.

[0068]The effect of nicotine or DMPP treatment on AMJ2-C11 cells was tested on TNF-α and IL-10 mRNA expression by RT-PCR. These cytokines are involved in the development of pulmonary inflammatory diseases such as HP, asthma and sarcoidosis (52-55). Nicotine and DMPP treatments showed a great decrease in TNF mRNA expression (up to a 98% reduction of expression in Lipopolysaccharides component of gram negative cell walls (LPS) stimulated and treated with 40 pM nicotine), but not in a dose-dependant manner (FIG. 3). Similar results were observed with SR-stimulated cells (FIG. 4). This non-dose dependant response can be explained by nicotinic receptor desensitization due to a large quantity of agonist in the medium. IL-10 mRNA expression was also impaired by nicot...

example 3

In Vitro Effects of Nicotinic Agonists on Co-Stimulatory Molecule Expression

[0070]The effects of nicotine and DMPP on B7 (CD80) molecule expression were tested in vitro. AMJ2-C11 cells (mouse alveolar macrophages, from the ATCC) were incubated with 40 μM nicotine or DMPP and stimulated with LPS (0.1 μg / ml) or SR antigen (50 μg / ml) for 48 hours. The percentage of expression of CD80 in treated cells was about one half of the expression found in LPS and SR stimulated non-treated cells (FIGS. 8 (a) and (b)).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
volumeaaaaaaaaaa
vascular permeabilityaaaaaaaaaa
Login to view more

Abstract

This invention relates to the use of nicotine receptor agonists for treating inflammatory diseases, including a variety of pulmonary diseases. Such agonists have fewer side effects than other anti-inflammatory drugs, such as steroids. Moreover, these agonists can be used alone or in combination with other anti-inflammatory drugs to alleviate pulmonary diseases.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application is a continuation of application Ser. No. 10 / 469,999, filed on Feb. 24, 2004, which is a National State entry of PCT / CA02 / 00412, filed on Mar. 25, 2002, which claims priority to Canadian Application No. CA 2,341,952, filed on Mar. 23, 2001.FIELD OF THE INVENTION[0002]The present invention relates to the treatment of inflammatory diseases, including a variety of pulmonary diseases, through the use or administration of nicotinic receptor agonists.BACKGROUND OF THE INVENTION[0003]Although we breathe more than one cubic meter of air every hour, our lung defense mechanisms usually deal with the large quantities of particles, antigens, infectious agents and toxic gases and fumes that are present in inhaled air. The interaction of these particles with the immune system and other lung defense mechanisms results in the generation of a controlled inflammatory response which is usually protective and beneficial. In general, t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/4965A61K31/465A61P11/00A61K45/00A61K31/00A61K31/495A61P11/06A61P29/00A61P43/00
CPCA61K31/495A61P11/00A61P11/06A61P11/08A61P29/00A61P43/00
Inventor CORMIER, YVONISRAEL-ASSAYAG, EVELYNEBLANCHET, MARIE-RENEE
Owner UNIV LAVAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap